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All cells export part of their intracellular content into the extracellular space through the 
release of various types of extracellular vesicles (EVs). They are synthetized either from 
the budding of the plasma membrane [i.e., microparticles (MPs, 150–300 nm size)] or 
from the late endosomes in which intraluminal vesicles progressively (ILVs) accumulate 
during their maturation into multivesicular bodies (MVBs). ILVs are then released into the 
extracellular space through MVB fusion with the plasma membrane [i.e., exosomes 
(50–100 nm size)]. In the context of metabolic diseases, recent data have highlighted the 
role of EVs in inflammation associated with pancreas dysfunction, adipose tissue 
homeostasis, liver steatosis, inflammation, and skeletal muscle (SkM) insulin resistance 
(IR). Among these insulin-sensitive tissues, SkM is the largest organ in human and is 
responsible for whole-body glucose disposal and locomotion. Therefore, understanding 
the contribution of SkM-EVs in the development of diabetes/obesity/dystrophy/,-related 
diseases is a hot topic. In this review, we have summarized the role of SkM-EVs in muscle 
physiology and in the development of metabolic diseases and identify important gaps 
that have to be filled in order to have more precise information on SkM-EVs biological 
actions and to understand the functions of the different subpopulations of SkM-EVs on 
the whole-body homeostasis.
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INTRODUCTION
Skeletal muscle (SkM) is the largest organ in the human body. It is responsible for whole-
body glucose and energy homeostasis, locomotion, and serves as body protein pool. It is 
a highly adaptable tissue responding to numerous environmental conditions (e.g., physical 
activity/sedentarity) and physiological challenges (e.g., nutrition, chronic inflammation) by 
changing fiber size and composition. These modifications are associated with the secretion 
of myokines into the extracellular milieu capable of modulating homeostatic adaptations 
in other peripheral organs (e.g., pancreas, adipose tissue, and bone) (Plomgaard et  al., 
2012; Guo et  al., 2017; Leal et  al., 2018; Lee and Jun, 2019) or involved in the process of 
myogenesis (Henriksen et  al., 2012). During the last decade, it has been shown that muscle 
cells also release extracellular vesicles (EVs) into the extracellular milieu, which represent 
new paracrine and endocrine signals that have modified our conceptual basis to explain 
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how muscles communicate to other organs (Guescini et  al., 
2010; Le Bihan et  al., 2012; Romancino et  al., 2013; Forterre 
et  al., 2014a). In this review, we  summarize the knowledge 
about SkM-EV contents (protein/nucleic acids/lipids) and on 
the role of SkM-EVs on muscle physiology and on the 
development of metabolic diseases. We also identify important 
questions that have to be  elucidated in order to have more 
precise information on SkM-EVs biological actions and to 
understand the functions of the different subpopulations of 
SkM-EVs on the whole-body homeostasis.
Skeletal Muscle Cells Release Various 
Types of Extracellular Vesicles
All cells export part of their content into various types of 
extracellular vesicles (EVs) (Figure 1A). They are synthetized 
either from the budding of the plasma membrane [i.e., 
microparticles (MPs), 150–300 nm size)] or from the maturation 
of late endosomes in which intraluminal vesicles (ILVs) 
progressively accumulate to form the multivesicular bodies 
(MVBs). ILVs are then released into the extracellular space 
through exocytosis of MVB [i.e., exosomes (EXO), 50–110 nm 
size] (Johnstone et  al., 1991; Colombo et  al., 2014). Larger 
vesicles are also formed during cell apoptosis when the cell 
cytoskeleton breaks up and induces the membrane to bulge 
outward (i.e., apoptotic bodies of 300–2,000 nm size) (Figure 1B; 
Caruso and Poon, 2018). It has been shown that apoptotic 
bodies are involved in tissue repair and angiogenesis during 
atherosclerosis (Zernecke et  al., 2009). MPs are involved in 
inflammation, coagulation, vascular function, and sepsis 
(Boulanger, 2010; Reich et  al., 2011; Das, 2019). They also 
release proteases for extracellular matrix degradation (Lozito 
and Tuan, 2012) and promote oncogene propagation among 
subsets of cancer cells (Al-Nedawi et  al., 2008). Shedding of 
membrane MP is also observed in normal conditions, e.g., 
MPs released from normal endothelial cells are implicated 
in angiogenesis. EXO are involved in cell homeostasis to 
eliminate unwanted and toxic cellular compounds (proteins, 
lipids, and nucleic acids) (Johnstone et  al., 1991; Desdin-
Mico  and Mittelbrunn, 2017). As these types of vesicles do 
not originate from the same cellular compartment their 
composition (lipid/nucleic acids and proteins) are different 
(Crescitelli et  al., 2013; Durcin et  al., 2017; Wei et  al., 2017; 
Tucher  et  al.,  2018).
To isolate these different types of EVs from muscle cell 
conditioned medium (Figures 1C,D) differential centrifugations 
are performed as described in Thery et  al. (2006) (Figure  2). 
After MP removal, and in order to enrich the preparation 
in small EVs, the supernatant is passed through a 0.22-μm 
filter and then is ultracentrifugated to collect small EVs enriched 
in exosomes. Sucrose or iodixanol gradients, or size exclusion 
chromatography with open columns are recommended to 
remove protein aggregates that may precipitate with the small 
EVs (Thery et  al., 2018; Jeppesen et  al., 2019). It has to 
be  noticed, however, that these different methods have not 
been compared for muscle-released EVs and may result in 
the selection or enrichment of specific EV subpopulations. 
A D
B
C
FIGURE 1 | Representation of muscle-release extracellular vesicles (EVs). (A) Exosomes are formed in late endosomes called multivesicular endosomes (MVBs), 
containing internal vesicles (ILVs) that pack and store molecules in membrane-bound structures. Endosomes are an intermediate compartment between the plasma 
membrane where endocytosis takes place and lysosomes where these molecules are degraded. MVB biogenesis can occur with the ESCRT machinery (ESCRT+) or 
without (ESCRT−) (Hessvik and Llorente, 2018). MVBs rich in lysobisphosphatidic acid (LBPA) but low in cholesterol migrate toward lysosomes and fuse with them. 
Those rich in cholesterol but low in LBPA migrate to the plasma membrane to fuse and release their ILVs as exosomes (Laulagnier et al., 2005; Colombo et al., 
2014). (B) Electron microscopy showing the release of apoptotic bodies from an apoptotic C2C12 myoblast (personal data from S. Rome) (scale = 1 μm).  
(C) Microparticles (MPs) represent a heterogeneous population of small plasma membrane vesicles (Morel et al., 2011). Electron microscopy of human myotubes 
showing the release of MPs from the plasma membrane (scale = 1 μm) (personal data from S. Rome). (D) Due to their small size exosome-like vesicles (ELVs)  
can be visualized only through electron microscopy. ELVs released from quadriceps explants labeled with anti-CD81 gold particles (personal data from S. Rome).
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As it is difficult to avoid contaminations of exosomes with 
other small vesicles, (i.e., small MP or small apoptotic bodies) 
and because no highly extensive vesicle purification was 
performed in published studies working on isolated EVs from 
SkM cells, SkM explants, or myofibers, we  will use the term 
of exosome-like vesicles (ELV) in this review to consider the 
small EV subpopulation’s heterogeneity.
The process of myogenesis involves a first step in which 
myoblasts proliferate until they reach confluence, then fuse to 
produce multinucleated myotubes which do not proliferate 
anymore. Nuclei are located at the periphery of the myofiber 
and the other organelles are squeezed in between myofibrils 
or between myofibrils and the plasma membrane. How myotubes 
and myoblasts, which are very different type of cells, generate 
these small ELVs has not been yet investigate. It has been 
described that myoblasts produce small ELVs (ELV-MB) (Guescini 
et  al., 2010; Forterre et  al., 2014a,b; Sork et  al., 2018) likely 
reflecting the intense macromolecule/RNA/lipids turn-over that 
occurs during cell proliferation (Johnstone et al., 1991; Desdin-
Mico and Mittelbrunn, 2017). Myotubes also release small ELVs 
(ELV-MT) (Figure 1D; Le Bihan et al., 2012; Romancino et al., 
2013; Forterre et  al., 2014a,b) and the presence of ELVs was 
also demonstrated in dispersed mouse myofibers from the 
mouse hindlimb muscles (De Gasperi et al., 2017). Romancino 
et  al. (2013) have suggested that ELV-MB and ELV-MT may 
have different origins and that ELVs from MT would be produced 
mainly through the budding of the plasma membrane. In their 
study, loss of Alix protein involved in ILV biogenesis in MVBs 
(Sun et  al., 2015) resulted in alteration of membrane budding, 
a decrease in the number of ELV released and a modifications 
of ELV-MT composition (of note, in this study the EV pellet 
was not filtered at 0.22 μm; thus, the authors may have worked 
with a pool of MPs and ELVs) (Romancino et  al., 2013). 
Interestingly, the involvement of Alix for EV release seems to 
occur only in muscle cells as the knockdown of Alix did not 
affect the number of ELVs released from human liver stem-
like cells (Iavello et  al., 2016).
MPs released from human MT were enriched in tetraspanin 
CD81 and in CLIC1 and galectin-1 (LGALS1) proteins and 
did not contain tetraspanins CD63, CD82, and CD9 which 
were found associated with ELVs from human MT (Figures 1D, 3; 
Le Bihan et al., 2012). Proteomic analyses indicated that ELV-MT 
contain few of the endosomal/lysosomal CD63 tetraspanin 
compared with CD81 or CD9 tetraspanin (Forterre et  al., 
2014a), known to be  also expressed at the plasma membrane1. 
Western blot quantifications also showed that CD81 was more 
enriched in ELV-MT than in ELV-MB (Forterre et  al., 2014a) 
and that Alix protein level was significantly enriched in ELVs 
released from myotubes than from myoblasts (Romancino et al., 
2013). Taken together, these data highlight two pathways for 
ELV release from muscle cells (i.e., for ELVs and MPs, 
respectively) and suggest that the ratio between ELVs and 
MPs may vary between proliferation and differentiation. The 
contribution of these two types of vesicles in muscle physiology 
has never been fully characterized, and their specific biological 
functions on recipient cells are not known.
Beside EVs biogenesis’ variability resulting in the release 
of different vesicle subpopulations, recent data from other cell 
types indicated that when sucrose gradient purifications were 
performed, small ELVs might be  composed of different 
subpopulations. For instance, ELVs released from colon carcinoma 
cell line LIM1863 (Tauro et  al., 2013), human dendritic cells 
(Kowal et al., 2016), human mast cell HMC-1 (Crescitelli et al., 
2013), and RBL-2H3 (Laulagnier et  al., 2005) are a mixture 
of two subpopulations of small EVs with distinct densities 
when separated on sucrose or iodixanol gradients. In addition, 
they are distinguished by their total RNAs, proteins, and lipids 
content too. For mesenchymal stem cells, at least three populations 
1 www.proteinatlas.org/ENSG00000110651-CD81/cell
FIGURE 2 | Currently used protocols to purify ELVs from skeletal muscle (SkM) cells conditioned medium, SkM explants, or myofibers. The origin/composition and 
the level of purity of the EV pellets from steps 1–3 have to be validated according the MISEV2018 guidelines (Thery et al., 2018).
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with specific protein and lipid contents were identified (Lai 
et  al., 2016). Based on the recent study of Jeppesen et  al. 
(2019), it is likely that these two populations represent exosomes 
and small MPs. For human muscle cells, iodixanol gradients 
have been performed with ELV-MT and resulted in the 
identification of five potential ELV-MT subpopulations with 
specific tetraspanin enrichments (Figure 3; Le Bihan et  al., 
2012). Interestingly, mitochondrial DNA (Guescini et al., 2010), 
histones, and nuclear proteins were also found in ELV-MB 
(Guescini et  al., 2010; Forterre et  al., 2014a; Sork et  al., 2018) 
and ELV-MT (Le Bihan et  al., 2012; Forterre et  al., 2014a). 
Although we  cannot exclude the presence of contaminations 
with small apoptotic bodies which are formed during myoblast 
apoptosis, it has to be  noticed that RNA/proteins of both 
nuclear and mitochondrial origins have been consistently 
identified in ELVs released from other cell types suggesting 
that SkM may also release EVs originated from different MVB 
subpopulations (Vesiclepedia: http://microvesicles.org/index.
html). Indeed, it has been shown that cells contain different 
MVB-like structures and some of MVBs contain vesicles of 
different sizes (small vesicles can be  inside larger ones) or 
filled with electron-dense material (Zabeo et  al., 2017). 
Interestingly, it was shown that mitochondria were able to 
release small vesicles from their membranes to deliver specific 
mitochondrial contents into late endosome/MVBs (Soubannier 
et al., 2012; Sugiura et al., 2014; Cadete et al., 2016). In addition, 
the formation of nuclear vesicles was also reported as 
non-canonical pathway for mediating nucleo-cytoplasmic 
transport of ribonucleoprotein particles in Drosophila larvae 
muscle (Speese et  al., 2012). All these data suggest a high 
level of material exchange between different types of MVB-like 
structures, which could result in the release of a heterogeneous 
population of SkM-ELVs and may explain the diversity of their 
protein contents. In line with this hypothesis, a new pathway 
was recently described to explain the presence of dsDNA and 
histones in small EVs. It would involve MVB and autophagy 
and the formation of an amphisome that, after fusion with 
the plasma membrane, would release dsDNA and histones in 
the extracellular space, as an exosome-independent mechanism 
(Jeppesen et  al., 2019). It is now of utmost importance to 
characterize SkM-EVs subpopulations, to understand their 
cellular origin, and to determine whether they may have distinct 
biological activities on recipient cells (Lasser et  al., 2018).
Composition of Skeletal Muscle-Released 
Extracellular Vesicles
Proteins
Proteomic analyses have identified two specific subsets of 
proteins for MPs and ELVs, released in the conditioned medium 
from human myotubes (Figure 4A; Le Bihan et  al., 2012). 
MPs were enriched in genes coding for proteins involved in 
“protein synthesis, folding, and trafficking,” “RNA post-
transcriptional modifications,” “translation modifications,” and 
“amino acid metabolism.” They were mainly cytosolic proteins, 
located in “endoplasmic reticulum,” “Golgi vesicles,” 
“mitochondria,” and “cytoskeleton.” Compared to MPs, human 
ELV-MT were enriched in proteins for “free-radical scavenging” 
and “cell-to-cell signaling and interactions.” Conversely to MP 
proteins, ELV-MT proteins were localized in “subplasma-
membrane cytoplasmic vesicles,” “endosomes,” “lysosome,” and 
“plasma membrane” (Le Bihan et  al., 2012), further suggesting 
that SkM would release small vesicles also through the budding 
of the plasma membrane (Romancino et  al., 2013). These 
comparative proteomic analyses indicated that ELV-MT proteins 
are mainly those endocytosed and delivered into endosomes 
for incorporation into MVBs or for degradation into lysosomes. 
The selection process involved in the delivery of some membrane 
proteins to ILVs of MVBs for destruction while others remain 
outside is not well understood. It has been found that 
ubiquitination was necessary the partitioning of mainly, but 
not all, membrane proteins into invaginating MVBs (Reggiori 
and Pelham, 2001; Stringer and Piper, 2011). In this way, 
FIGURE 3 | Summary of all vesicles identified in the conditioned-medium from skeletal muscle (SkM) cells based on the detection of specific subsets of 
tetraspanins by proteomics or Western-blot.
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endosomes/MVBs regulate the composition of plasma membrane 
and thus play a pivotal role in a vast array of biological 
functions. For instance, the endosomal system functions like 
a digital-analogue computer that regulates the specificity and 
robustness of the insulin signaling response in the SkM (i.e., 
insulin induces translocation of key signaling proteins into 
endosome) (Balbis et al., 2000; Jethwa et al., 2015). The presence 
of proteins involved in gluconeogenesis, pyruvate metabolism, 
and biosynthesis of carboxylic acids (e.g., TPI1, PGK1, GAPDH, 
GPI, ENPP1, and ACLY) also suggests that ELV-MT release 
could represent an important pathway for the turnover of 
proteins involved in the regulation of SkM metabolism 
(Figure 4B). Gene enrichment analyses of the proteins commonly 
identified in ELV-MT from human (Le Bihan et  al., 2012) 
and murine (Forterre et al., 2014a) SkM cells further confirmed 
that ELV-MT are enriched in proteins involved in exosome 
formation and intracellular trafficking (e.g., endocytosis, vesicle 
fusion, and transport, and signaling pathways involved in vesicle 
cellular localization) (Figure 4B). Interestingly, the majority 
of the proteins identified in ELV-MB was also found in ELV-MT 
(Figure 5A). This result indicates that although the organization 
of the cellular organelles and the plasma membrane of myoblasts 
changes dramatically during differentiation consequently to the 
formation of a single functional unit, SkM-ELV composition 
remains quite constant. This result further supports the concept 
that proteins sorting into ELVs appears to be  selective and 
almost the same subset of proteins is exported whatever type 
of cell considered. Figure 5B shows the overlapping between 
three independent proteomic analyses from C2C12 myoblasts 
and the 59 proteins commonly identified are listed in Table 1. 
Of note, only CD63 was commonly identified among all 
tetraspanins (Figure 3) likely reflecting the protocol variabilities 
for SkM EV purifications (Jeppesen et  al., 2019).
In order to determine the contribution of the ELV-associated 
proteins among the set of proteins isolated from muscle cell 
secretome, a functional enrichment analysis was performed 
by comparing the set of secreted proteins from C2C12 
myoblasts (Henningsen et  al., 2010) with the set of proteins 
identified from ELV-MB (Figure 5C; Forterre et  al., 2014a). 
None of the GO categories previously found as significantly 
enriched in ELV proteins (Figure 4B) was identified in the 
635 secreted proteins. By contrast, the C2C12 secretome 
was significantly enriched in GO term “cytokines.” A similar 
result was obtained for human muscle cells (Le Bihan et  al., 
2012). These data indicated thus that SkM cell uses distinct 
pathways for the release of distinct protein subsets with 
likely distinct biological actions. One exception is the protein 
C1QTNF3 (Cartonectin) found in ELV-MT (Forterre et  al., 
2014a). Cartonectin is a new cytokine, paralog of adiponectin 
contained as a transmembrane protein in adipocyte-released 
EVs and in EVs isolated from serum (Phoonsawat et  al., 
2014). The function of this family of cytokines in ELVs is 
presently unknown.
Lipids
Lipids are essential constituent of ELV membranes, and several 
studies have described that specific lipids are enriched in ELVs 
compared with the parent cells (Skotland et  al., 2017), i.e., a 
cholesterol, sphingomyelin, phosphatidylcholine, phosphatidylserine, 
phosphatidylethanolamine, and diacylglycerol. This specific lipid 
enrichment, their membrane high protein/lipid ratio and 
asymmetric distribution are associated with a higher membrane 
rigidity in ELVs in comparison with parent cells (Record et  al., 
2018). Lipidomic and proteomic analyses on ELVs and MPs 
released from three different cell lines have indicated that lipidomes 
of ELVs, MP and secreting cells were more similar to each 
A B
FIGURE 4 | (A) Proteomic analyses identified specific subsets of proteins in MPs and ELVs released from differentiated human SKM cells [full list of proteins are in 
Le Bihan et al. (2012)], protein are identified from protein fragments). (B) Significant GO biological functions enriched in genes commonly identified C2C12 
myotubes- and primary human myotubes-ELVs isolated from conditioned medium. Proteomic data are from Forterre et al. (2014a) and Le Bihan et al. (2012) and 
were analyzed with PANTHER version 11 (Mi et al., 2017).
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other than their proteomes are (Haraszti et  al., 2016). For 
muscle cells, only one study has determined the fatty acids 
(FA) composition of ELV-MT. As shown on Figure 5D, ELV-MT 
are enriched in palmitic acid, stearic acid, oleic acid, palmitoleic 
acid, and lauric acid compared to others FA (Aswad et  al., 
2014). These fatty acids are used for energy production or to 
produce phospholipids for phospholipid bilayers out of all cell 
membranes. Interestingly, ELVs released from C2C12 myotubes 
treated with palmitate were enriched in palmitate compared 
to BSA-treated cells (Aswad et  al., 2014). As accumulation of 
intracellular fatty acids is associated with insulin resistance 
and/or an impaired glucose metabolism, the release of ELVs 
may represent a form of protection for the cell, to prevent 
accumulation of intracellular fatty acids.
RNA
ELV preparations from various cell types have demonstrated 
that they contain distinctive repertoires of RNA populations 
including transcripts (Valadi et  al., 2007; Skog et  al., 2008) 
and non-coding RNAs, i.e., long non-coding RNA, microRNAs 
(miRNAs), piwi protein interacting RNA (piRNA), small nuclear 
RNA (snRNA), small nucleolar RNA (snoRNA), small Cajal 
body-specific RNA (scaRNA), circular RNA (circRNA), sc RNA 
Y, natural antisense RNA (asRNA), ribosomal RNA (rRNA), 
and vault RNA (vRNA) (Nolte-'t Hoen et al., 2012). Interestingly, 
while cellular RNAs are enriched in full-length long RNA 
species, ELVs are enriched in shorter RNA species (≤200 
nucleotides) including short transcripts, fragmented mRNAs 
(Batagov and Kurochkin, 2013), and small RNAs (i.e., miRNA, 
snoRNA, snRNA, Y RNA, and vault RNA). As the sequencing 
of these different populations often rely on separate libraries 
the direct comparisons between them are not always 
straightforward, but these analyses clearly indicated a differential 
profile of ncRNA subsets between parental cells and EVs 
(Guduric-Fuchs et  al., 2012). In the case of SkM cells, it was 
shown that C2C12 ELV-MB were also enriched in small RNAs 
subsets compared with C2C12 parental cells (Figure 6A; Sork 
et  al., 2018). Only the small RNA population has been further 
analyzed (Forterre et  al., 2014b; Sork et  al., 2018; Xu et  al., 
2018), and was found highly enriched in piRNAs and miRNAs 
(Figure 6B; Sork et  al., 2018). For the majority of miRNAs, 
a good correlation was observed between miRNA levels in 
ELV-MB vs. MB in two independent studies (Forterre et  al., 
2014b; Sork et  al., 2018), and between ELVs released from 
myofibers vs. myofibers (De Gasperi et  al., 2017), suggesting 
that export of miRNAs into ELVs would permit to control 
their intracellular concentrations. In silico predictions of the 
most concentrated miRNAs in ELV-MB (Sork et  al., 2018) 
indicated that they could collectively regulate important cellular 
pathways for muscle physiology, i.e., signaling pathways involved 
in the regulation of muscle mass (PI3K-Akt, insulin, MAPK, 
TGF-beta, proteolysis, and calcium), in the neuromuscular 
junction, in immune response, and in calcium signaling and 
cytoskeleton (Figure 6C). Interestingly, all studies reported also 
that individual miRNAs deviate from this relationship, i.e., 
some miRNAs expressed in muscle cells were not detected in 
ELV-MB (Forterre et  al., 2014b) and/or ELV-MT (Figure 6D; 
Forterre et  al., 2014b); other were found at higher rate in 
ELV-MB vs. myoblasts [miR-451, miR-6239, miR-6,240, 
miR-6236, miR-144, miR-223, miR-5112, miR-3062, miR-142a, 
and miR-2137  in Sork et  al. (2018)]. Similarly, miR-720 was 
enriched in myofiber-derived ELVs compared with parent 
A B
C D
FIGURE 5 | (A) Overlap between the number of proteins from C2C12 ELV-MB and ELV-MT (see Forterre et al., 2014a for a full list of proteins, proteins are identified 
from protein fragments). (B) Overlap between three independent protomic analyses from C2C12 ELV-MB. (C) Left: overlap between the protein content of ELV-MB 
and the secretome from C2C12 myoblasts (Forterre et al., 2014a); right: overlap between the protein contents of ELV-MT and the secretome from human 
differentiated MT (Le Bihan et al., 2012). Only significant GO functions between the two sets of proteins are indicated. (D) Fatty acid composition of ELV-MT from 
C2C12 (Aswad et al., 2014).
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myofibers and inversely for miR-1 (De Gasperi et  al., 2017). 
A third category was composed of miRNAs that were only 
found in ELVs and not detectable in the parental cells 
(Figure 6D). On the contrary, miR-147, miR-30b-3p, miR-467c, 
miR-615-3p, miR-669a, miR-677, miR-28a-3p, and miR-29-2-5p 
were never detected in C2C12-released ELV-MB or ELV-MT 
TABLE 1 | Proteins identified in 3 independant proteomic analyses from C2C12 ELV-MB.
Gene symbols Names
Aldoa aldolase A, fructose-bisphosphate
Ldha lactate dehydrogenase A
Gapdh Glyceraldehyde 3-phosphate dehydrogenase
Anxa1 annexin A1
Anxa2 annexin A2
Anxa3 annexin A3
Anxa4 annexin A4
Anxa5 annexin A5
Anxa6 annexin A6
Arhgdia Rho GDP dissociation inhibitor (GDI) alpha
Cct3 chaperonin containing Tcp1, subunit 3 (gamma)
Cct4 chaperonin containing Tcp1, subunit 4 (delta)
Cct5 chaperonin containing Tcp1, subunit 5 (epsilon)
Cct6a chaperonin containing Tcp1, subunit 6a (zeta)
Cct8 chaperonin containing Tcp1, subunit 8 (theta)
Cd63 CD63 antigen
Clic1 chloride intracellular channel 1
Cltc clathrin, heavy polypeptide (Hc)
Des desmin
Eef1a1 eukaryotic translation elongation factor 1 alpha 1
Eef2 eukaryotic translation elongation factor 2
Ehd1 EH-domain containing 1
Ehd4 EH-domain containing 4
Eif4a1 eukaryotic translation initiation factor 4A1
Ezr ezrin
Fn1 fibronectin 1
Gnb2 guanine nucleotide binding protein (G protein), beta 2
Hspa8 heat shock protein 8
Hspb1 heat shock protein 1
Igsf8 immunoglobulin superfamily, member 8
Ipo5 importin 5
Itgb1 integrin beta 1 (fibronectin receptor beta)
Kpnb1 karyopherin (importin) beta 1
Msn moesin
Myh9 myosin, heavy polypeptide 9, non-muscle
Pdcd6 programmed cell death 6
Pdcd6ip programmed cell death 6 interacting protein
Psmc6 proteasome (prosome, macropain) 26S subunit, ATPase, 6
Ptgfrn prostaglandin F2 receptor negative regulator
Ran RAN, member RAS oncogene family
Rplp0 60S acidic ribosomal protein P0
Rps2 ribosomal protein S2
Rps3 Ribosomal Protein S3
Rps4x ribosomal protein S4, X-linked
Rps8 ribosomal protein S8
Rpsa ribosomal protein SA
Tpi1 triosephosphate isomerase 1
Tpt1 tumor protein, translationally-controlled 1
Tubb2b tubulin, beta 2B class IIB
Tubb3 tubulin, beta 3 class III
Tubb5 tubulin, beta 5 class I
Tubb6 tubulin, beta 6 class V
Uba1 ubiquitin-like modifier activating enzyme 1
Vcl vinculin
Vcp valosin-containing protein
Vim vimentin
Ywhae tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide
Ywhaq tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide
Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide
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(Forterre et  al., 2014b). Taken together, these data indicated 
that the packaging of some specific miRNAs into muscle-released 
ELVs is selective. How miRNAs are loaded into ELVs is poorly 
understood and may be  resulting from different mechanisms, 
i.e., (1) the 3′ end uridylation of miRNA directs these small 
RNAs to sites of ELV biogenesis, while adenylation appears 
to have the opposite effect (Koppers-Lalic et  al., 2014); (2) 
the association of miRNAs with RNA-binding proteins which 
are targeted to MVBs through post-translation modifications 
(i.e., sumoylation of the ribonucleoprotein hnRNPA2B1, which 
recognizes the GGAG motif in a subset of miRNAs is associated 
with miRNA loading into MVB) (Villarroya-Beltri et al., 2013); 
(3) the association of miRNAs with proteins involved in their 
synthesis and their function, which are loaded into ELVs [i.e., 
AGO2 (Gibbings et  al., 2009) and the elements of the RISC-
loading (silencing) complex (ALIX) (Iavello et  al., 2016)]; (4) 
the association with YBX1 localized in P-bodies which are 
closely juxtaposed to MVBs. It is hypothesized that YBX1 may 
complex with miRNAs whose mRNA targets are not expressed. 
This association would result in their sorting into MVBs for 
export by ELVs (Shurtleff et  al., 2016).
Unlike miRNAs, there was no correlation between ELV-MB 
and cellular concentrations in myoblast for piRNAs (Sork et al., 
2018). C2C12 ELV-MB also contained tRNAs (Sork et al., 2018) 
and Y RNA (mainly RNY1) (Forterre et  al., 2014b; Sork et  al., 
2018). The function of these non-coding RNA in muscle-released 
ELVs has not been yet identified but based on recently published 
data from other cell types; they could participate in the biological 
action of SkM-ELVs (Cambier et  al., 2017).
Messenger RNAs were also detected by using DNA microarrays, 
in ELVs and MPs released from human SkM cells (Le Bihan 
et al., 2012). Respectively, 185 and 4,431 transcripts were identified 
in ELVs and MPs. Hierarchical clustering showed that the mRNA 
cargos of ELVs and MPs were more closely related to each other 
than to the expression pattern of the secreting myotubes. The 
abundance of the 185 ELV mRNAs correlated with their abundance 
in myotubes, indicating that myotubes release a specific subset 
of transcripts in ELVs, and not only the most concentrated one. 
ELVs were significantly enriched in transcripts encoding receptors 
and ionic channels, and regulators of transcription in particular 
zinc-finger transcription factors (Le Bihan et  al., 2012).
Biological Action of Skeletal  
Muscle-Released Extracellular Vesicles
Since the discovery that ELV cargos released from a specific cell 
type can be  incorporated into various recipient cells (including 
a re-uptaking by the releasing cells) and by this way can regulate 
their fate (Valadi et al., 2007), numerous studies have demonstrated 
the involvement of EVs in health (i.e., embryogenesis and 
development, tissue homeostasis) and diseases (i.e., cancer metastasis, 
inflammatory diseases, and metabolic diseases) (Figure  7). In 
that context, it has been found that SkM-released EVs have 
important paracrine actions that would participate in muscle 
physiology and may have an impact at the whole-body homeostasis.
A C
B D
FIGURE 6 | (A–C) were built from the sequencing data published in Sork et al. (2018). (A) Percentage of small and large RNAs in C2C12 myoblasts and their 
released ELV-MB. (B) Number small RNA species in C2C12 myoblasts vs. ELV-MB expressed as percentages. (C) Functional enrichment analyses of the predicted 
target genes from ELV-MB miRNAs. Target predictions and the identification of significant biological pathways were performed with DIANA-microT-CDS and mirPath 
v.3 (http://snf-515788.vm.okeanos.grnet.gr). (D) Overlap between the miRNA species found in muscle cells and their respective ELVs (n = 3). The same quantity of 
total RNA was used as starting material for qRT-PCR (Forterre et al., 2014b).
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As protein and miRNA compositions were different between 
ELV-MB and ELV-MT, it was postulated that they might 
be  involved in the process of myogenesis. Indeed, it was shown 
that both ELV-MT protein and miRNA contents were transferred 
into proliferating myoblasts (Forterre et al., 2014a,b). Treatment 
of myoblasts with ELV-MT but not ELV-MB resulted in a 
decrease in myoblast proliferation and in the induction of early 
markers of differentiation (e.g., myogenin mRNA) (Forterre 
et  al., 2014a). Bioinformatic analyses revealed that predicted 
target genes of differentially expressed miRNAs between ELV-MB 
and ELV-MT were mainly involved in the control of signaling 
pathways, and particularly the Wnt signaling pathway known 
to be  regulated during myogenesis (Tanaka et  al., 2011). 
Additionally, it was demonstrated that ELV-MT miRNAs were 
enriched in miRNA species targeting the 3’-UTR of sirt 1, a 
gene involved in muscle cell proliferation. Therefore, through 
the ELV route MT-ELV miRNAs could reduce the level of 
endogenous Sirt1  in myoblasts thus inducing cell differentiation 
(Forterre et al., 2014b). Furthermore, it was found that removing 
ELVs from bovine serum of cell culture, affected C2C12 
proliferation (i.e., decrease of Cyclin D1 and Sirt1 mRNA levels) 
and committed cells to differentiate prematurely (induction of 
myogenin mRNA before myoblast fusion) (Aswad et  al., 2016). 
In addition to observations that bovine ELVs can transfer specific 
signals to cells from unrelated species (mice C2C12), this result 
also suggests that ELVs in mammalian serum might have 
unsuspected functions during embryogenesis and in the regulation 
of cellular adaptations that lead to muscle hypertrophy, hyperplasia, 
and metaplasia. In line with this hypothesis, proliferation of 
C2C12 myoblasts is increased after 24  h of treatment with 
serum ELVs from mice suffering from Duchenne muscular 
dystrophy (mdx mice) compared with ELV-depleted serum 
(Matsuzaka et  al., 2016), thus suggesting an important role of 
blood ELVs on the regulation of myogenesis and muscle mass.
In adult, myogenesis is stimulated in response to muscle 
damage and a role of SkM-ELVs was suggested in the control 
of muscle mass. In the context of hypertrophy, SkM satellite 
cells are activated to give rise to myogenic progenitor cells (MPCs) 
within the extracellular matrix (ECM) located around the fibers. 
It was found that MPCs secrete ELVs containing miR-206, which 
repressed the ribosomal binding protein 1, a master regulator 
of collagen biosynthesis, in fibrogenic recipient cells. This would 
prevent excessive ECM deposition for optimal muscle remodeling 
in response to hypertrophic stimuli (Fry et  al., 2017). These data 
have provided insights into how skeletal stem and progenitor 
cells interact with other cell types to actively control their 
extracellular environments for tissue maintenance and adaptation. 
They have also provided a new mechanism to explain the fibrotic 
pathogenesis associated with other SkM alterations (i.e., muscular 
dystrophy, aging) in which satellite cell activity is perturbated 
and thus likely the release/composition of ELVs.
In the context of atrophy, treatment of C2C12 myotubes 
with dexamethasone for 48  h reduced the intracellular level 
of miR-23a but increased its ELV-MT abundance. As 
dexamethasone did not alter the number of ELVs released 
these data suggested that atrophy-inducing conditions lead to 
a selective packaging of miRNAs into ELV-MT (Hudson et  al., 
2014), thus changing the delivered message to recipient cells. 
In line with this hypothesis, it was demonstrated that after 
denervation, muscle fiber released a new population of ELVs 
enriched in miR-206 able to downregulate the expression of 
Smarcd1 and Runx2 proteins into NIH3T3 adipocytes (De 
Gasperi et al., 2017). It was also found that myoblasts incubated 
with ELVs released from myotubes pre-treated with H2O2 that 
mimics an oxidative stress, leads to a reduction in myotube 
diameter and to a stimulation of myoblast proliferation (Guescini 
et  al., 2017). Similar results were obtained when myotubes 
were treated with a pro-inflammatory cytokine mixture of 
TNF-alpha and INF-gamma (Kim et  al., 2018), suggesting that 
in addition to myogenesis, ELV-MT would also participate in 
the maintenance and regeneration of SkM mass following injuries.
In the context of metabolic diseases, in vivo data showed 
that palmitate-induced SkM insulin-resistance triggered the 
release of a new population of ELV-MT enriched in palmitate, 
FIGURE 7 | Summary of the roles of exosome-like vesicles released from skeletal muscle (SkM) cells, published so far.
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in diet-induced obese mice (DIO) compared normal chow diet 
mice (NCD) (Aswad et  al., 2014). It was demonstrated that 
palmitate contained in ELV-MT from DIO mice was transferred 
in recipient myotubes and resulted in the up-regulation of 
240 genes involved in cell cycle and cellular adhesion. Among 
them, the pro-inflammatory cytokine IL-6 and the cell cycle 
regulator cyclin D1 were strongly upregulated, whereas Glut4 
involved in glucose uptake was downregulated. In addition, 
muscle differentiation markers (myogenin, MyoD1, and CKMT2) 
were down-regulated showing that ELV-MT enriched in palmitate 
affected muscle phenotype. In addition to the release of a 
specific population of ELVs, mice fed with a palmitate-enriched 
diet released more ELV-MT (Aswad et  al., 2014). It is likely 
that excessive concentration of circulating palmitate and saturated 
fatty acids associated with this specific high-fat diet had increased 
the concentration of intra-muscular ceramides that regulate 
ELV release from muscle (Matsuzaka et al., 2016). Interestingly, 
it has been found that intraperitoneal injections for 5–10  days 
of an inhibitor of ceramide synthesis improved muscle function 
and structure in mdx mice vs. untreated mdx animals (Matsuzaka 
et  al., 2016). Although the composition and the biological 
action of SkM-ELVs from of these treated animals were not 
determined, it is a proof-of-concept that modulation of ELV 
release might be a therapeutic approach to regulate deleterious 
organ cross-talks associated with the transfer of deleterious 
EV cargos (e.g., the transfer of deleterious lipids during the 
development of metabolic diseases associated with high-fat diet).
Indeed, although communication between SkM and other 
tissues appears to be of importance in the development of various 
diseases, investigations to determine signals underlying these 
connections have been widely limited to the roles of cytokines. 
Recently, the possibility that SkM-ELVs could also act at systemic 
level has been studied in the context of type 2 diabetes associated 
with obesity (Jalabert et  al., 2016). Intraperitoneal injections of 
fluorescent SkM-ELVs resulted in the fluorescent labeling of 9 
organs in mice [i.e., brain, liver, heart, lungs, gastro-intestinal 
tract, spleen, pancreas, and kidney in addition to SkM (Aswad 
et  al., 2014; Wiklander et  al., 2015; Jalabert et  al., 2016)]. ELVs 
collected from conditioned medium of SkM explants from DIO 
mice induced specific transcriptional signatures in pancreatic 
MIN6B1 recipient cells compared to SkM-ELVs from NCD mice. 
Microarray data analyses showed that the expressions of 460 
mRNAs were significantly modulated including genes involved 
in immune responses known to be  affected in pancreatic islets 
of diabetic patients (Esser et  al., 2014; Jalabert et  al., 2016). 
Additional bioinformatic analyses combined with in vitro 
experiments demonstrated that SkM-ELVs mediated the transfer 
of miRNAs from insulin-resistant muscles into MIN6B1 and 
affected the expression of proliferative genes such as Ptch1 (Jalabert 
et al., 2016). These data suggested for the first time that SkM-released 
ELVs might transmit signals to the pancreas during the development 
of insulin-resistance. Because SkM-ELVs have no effect on insulin 
secretion, it would suggest that muscle-released ELVs would 
contribute to adaptations in beta cell mass occurring during 
insulin-resistance associated with obesity, at least in mice (Stamateris 
et  al., 2013). As SkM is the unique organ for exercise, the 
variations of blood EV concentrations after physical activity have 
been studied (Frühbeis et  al., 2015). The results indicate that a 
single bout of exhaustive exercise triggers the release of EVs 
with the size and marker profile of exosomes, which are cleared 
from the circulation during the early recovery period after cycling, 
but stay elevated after running exercise.
However, the clinical significance of these studies remains 
speculative until now and scientists have to be  cautious not to 
over-interpret these data until the development of physiological 
models which would permit to follow EVs in blood vessels. 
Indeed, all results indicating a possible transfer of information 
between muscle cells and other tissues are based on in vitro 
data only. At current time, it not known whether SkM-ELVs 
could reach the blood circulation and have systemic actions. 
Recently, ELVs containing alpha-sarcoglycan (SGCA) a component 
of the dystrophin-glycoprotein complex involved in the stability 
of muscle fiber membranes, were found in human plasma 
(Guescini et  al., 2015). These ELVs were also positive for CD81, 
TSG101 and miR-206, known to be  highly expressed in SkM. 
Therefore, the authors of this study suggested that these SGCA 
positive ELVs might originate from SkM-ELVs and could be used 
as SkM liquid biopsies. Although we  exclude this possibility, it 
has to be  mentioned that SGCA and miR-206 are expressed in 
mainly other tissues (Mitchelson and Qin, 20152) suggesting 
that the origin of the circulating pool of SGCA-positive ELVs 
is more complex and not only the result of SkM ELV secretion. 
In an attempt to follow muscle-released ELVs in blood, fluorescent 
ELVs were injected in the right tibialis anterior (TA) from mouse 
(Jalabert et  al., 2016). Twenty-four hours after injection, 
fluorescence was detected in the left TA and in the right quadriceps 
too, suggesting again a paracrine-like action of muscle-released 
ELVs. Although these data strongly suggest that SkM can release 
ELV in blood, the generation of transgenic animals expressing 
GFP in SkM-released ELVs would help to quantify the impact 
of SkM-ELVs in vivo in the cross talks between SkM and key 
metabolic organs. Such model would also permit to identify all 
subtypes of EVs released from SkM cells in order to decipher 
their mode of biogenesis, and to understand how to modulate 
their release at the cellular level and to impact on their target 
tissues at the whole-body level.
CHALLENGES AND FUTURE DIRECTIONS
The release of EVs with biological properties from muscle cells 
is an exciting new discovery given the importance of SkM in 
the regulation of glucose homeostasis and as organ of locomotion. 
Further studies are now required to determine the exact roles 
of these SkM-EVs at the whole-body level. In addition, it is 
important to identify the pathophysiologic conditions that 
influence their biogenesis, their compositions and fate. In the 
context of metabolic diseases or muscle-related pathologies, it 
is important to determine whether MVB biogenesis and EVs 
release might be  new targets for therapy. Presently, this aspect 
is more or less considered by pharmaceutical companies to 
treat alterations of glucose/lipid metabolism, but the consequences 
2 www.genecards.org
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on EV release/composition are not known, e.g., statins, used 
to reduce cholesterol level in patients and to prevent cardiovascular 
diseases target chemokines to MVBs in endothelial cells (Hol 
et al., 2012); metformin, the well-known antidiabetic drug affects 
the endosomal pathway by modulating pH levels in recycling 
endosomes and MVB (Kim et  al., 2016; Kim and You, 2017). 
How these drugs affect EV release and compositions and 
participate in the side effects of the treatments is presently 
unknown, and has never been suggested. Beside to the use of 
drugs to modulate EV release, recent data suggest that EVs 
from healthy subjects might be used in the treatment of obesity, 
T2DM, and aging-associated metabolic disorders. Indeed, 
injections of adipose tissue macrophage-derived EVs isolated 
from lean mice improved glucose tolerance and insulin-sensitivity 
of diet-induced obese mice (Ying et  al., 2017). Similarly, the 
injection of 3-month-old mice blood EVs to 18-month-old mice 
reversed the expression aging-associated biomarkers (Lee et  al., 
2018). The injection of MSC-derived EVs was found more 
efficient than the use of MSC in treating stroke (Chang et  al., 
2018). Based on these pre-clinical data, we  can speculate that 
blood EVs isolated from athletes following exercise would transfer 
some of the beneficial systemic effects of exercise in patient 
suffering from metabolic disorders or SkM alterations (Frühbeis 
et al., 2015; Lovett et al., 2018). For example, it was demonstrated 
that endurance exercise induced the release of procoagulant 
MPs from blood cells in healthy subjects (Sossdorf et al., 2010). 
The authors of this study suggested that they would participate 
in the positive effect of exercise on vessel repair and wound 
healing, both affected in T2DM patients. Whether SkM-EVs 
from healthy subjects might be used to treat metabolic alterations 
or SkM dysregulation has never been envisaged.
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